Print
20 January 2014
Marchmont Innovation News
In 2013, Russia’s nanotech companies generated about $1.5bn worth of products, according to preliminary results voiced by Anatoly Chubais. The Rusnano president made this estimate, reported by Russian business daily RBC, at a most recent meeting with Prime Minister Dmitry Medvedev of Russia.
“We have our main KPI to focus on, and this is output volumes. In 2011, we only had about $30m; the next year it was $380m already,” Mr. Chubais said, adding that official data would soon come from Rosstat [Russia’s federal statistics agency – Editor’s note]. “We can see even now from our tentative estimates that we made it with $1.5bn last year,” the head of Russia’s nanotech giant claimed.
According to Mr. Chubais, Rusnano has facilitated the launch of 53 new nanotech-focused factories in Russia since its start in 2007. The key guideline for Rusnano to invest is finding a private co-investor willing to kick in. “To each ruble we invest, our co-investors add between 1.5 and 2 rubles,” the Rusnano president said.
Prime Minister Medvedev emphasized the importance of “sticking to this key guideline in the future.”
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.